Entelos Inc

Type: Company

Name: Entelos Inc

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Computational Biology Market - New Market Research Report Published by Transparency Market Research

Entities: Computational Biology, Market, Drugs

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Institute for Systems Biology

Entelos and Institute for Systems Biology Partner to Deliver Breakthrough Insights into Novel Drug Development

Collaboration connects gene expression data and physiological mechanistic model simulations that should illuminate best treatment for selected patients. Entelos Holding Corp. (“Entelos” or “the Company”), a premier provider of physiological system modeling ... [Published PRWeb - May 14 2013]

Entities: Entelos Inc, Institute for Systems Biology, Gene Expression, Decrypt, Biology

First reported Feb 05 2013 - Updated Feb 05 2013 - 1 reports

Accelrys Inc

Entelos Expands Executive Team

Veteran executives from the scientific software community, Dr. Mike Davies and Dr. Dominic John, join growing Entelos Entelos Holding Corp. (“Entelos” or the “Company”), a premier provider of physiological system modeling and services that help pharmaceutical ... [Published PRWeb - Feb 05 2013]

Entities: Entelos Inc, Mike Davies, Dominic John, Accelrys Inc

Quotes

According to a new market report published by , "Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018" in 2013, the global computational biology market was valued at USD 760 million and is expected to grow at a CAGR of 21...

Computational Biology Market - New Market Research Report Published by Transparency Market Research [Published PRWeb - May 14 2013]

...models needed to accelerate timelines and reduce failure rates in pharma and biotech R&D," said Shawn O’Connor, President and CEO of Entelos. "We anticipate that systems biology, pharmacy, and biochemistry candidates will find this an invaluable tool. Our large, sophisticated models cover enough of the body’s interconnected physiology that they can simultaneously assess efficacy of diabetes treatments and cardiac event risk. They can also illuminate translational efficacy issues, focus early clinical research, and can suggest new biomarker and biosignature patterns. As the pharmaceutical and biotechnology industries face increasing pressure, the benefits of training more scientists in academic institutions in these critical methodologies is more important than ever. We believe our academic licensing program can drive academic innovation and expand the base of systems biology expertise available to industry." About Entelos:

Entelos Announces New Release of PhysioLab Modeler® Software and... [Published PRWeb - Oct 16 2012]

More Content

sort by: Date \| Relevance
Computational Biology Market - New Market Resea... [Published PRWeb - May 14 2013]
Entelos and Institute for Systems Biology Partn... [Published PRWeb - May 14 2013]
Computational Biology Market - Global Industry ... [Published Individual.com - May 08 2013]
Computational Biology Market Is Expected to Rea... [Published WVNS - May 07 2013]
Entelos Expands Executive Team [Published PRWeb - Feb 05 2013]
Entelos Announces New Release of PhysioLab Mode... [Published PRWeb - Oct 16 2012]
Early Toxicology Testing Market, Transdermal Dr... [Published PRWeb - Oct 05 2012]
Entelos Signs Agreement with the Biomarkers Con... [Published PRWeb - Sep 05 2012]